Targeting BCL2 family in human myeloid dendritic cells: A challenge to cure diseases with chronic inflammations associated with bone loss

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Olsson Åkefeldt, Selma ^a,b,c,d,e   Ismail, Mohamad Bachar ^b,c,d,e   Valentin, Hélène ^b,c,d,e   Aricò, Maurizio ^f   Henter, Jan Inge ^a   Delprat, Christine ^b,c,d,e,g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Univ Claude Bernard   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f UNIVERSITY OF FLORENCE   (Italy)

^g INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; BIM PROTEIN; CD209 ANTIGEN; CLADRIBINE; COLONY STIMULATING FACTOR 1; CYTARABINE; FAS LIGAND; INTERLEUKIN 1; INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISONE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN MCL 1; PUMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; VINBLASTINE; VINCRISTINE; ANTIINFLAMMATORY AGENT; BCL2-RELATED PROTEIN A1; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1;

APOPTOSIS; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE ASSOCIATION; HUMAN; IMMUNOLOGICAL TOLERANCE; LANGERHANS CELL HISTIOCYTOSIS; MYELOID DENDRITIC CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BONE; BONE MARROW CELL; CELL FUSION; DENDRITIC CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HISTIOCYTOSIS, LANGERHANS-CELL; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PREVENTION AND CONTROL; DRUG ANTAGONISM; DRUG EFFECT;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE RESORPTION; CELL FUSION; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INTERLEUKIN-17; MOLECULAR TARGETED THERAPY; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; MYELOID CELLS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 84878623344     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/701305     Document Type: Review

References (76)

1. Cheong C., Matos I., Choi J. H., Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 2010 143 416 429
2. Vidalain P. O., Azocar O., Lamouille B., Astier A., Rabourdin-Combe C., Servet-Delprat C., Measles virus induces functional TRAIL production by human dendritic cells. Journal of Virology 2000 74 1 556 559 2-s2.0-0033988563 (Pubitemid 30002941)
3. Griffith T. S., Wiley S. R., Kubin M. Z., Sedger L. M., Maliszewski C. R., Fanger N. A., Monocyte-mediated tumoricidal activity via the tumor necrosis factor- related cytokine, TRAIL. Journal of Experimental Medicine 1999 189 8 1343 1354 2-s2.0-0033583433 10.1084/jem.189.8.1343 (Pubitemid 29198271)
4. Rivollier A., Mazzorana M., Tebib J., Piperno M., Aitsiselmi T., Rabourdin-Combe C., Jurdic P., Servet-Delprat C., Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004 104 13 4029 4037 2-s2.0-10244259169 10.1182/blood-2004-01-0041 (Pubitemid 39620153)
5. Fujikawa Y., Quinn J. M. W., Sabokbar A., McGee J. O. D., Athanasou N. A., The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996 137 9 4058 4060 2-s2.0-0029793393 10.1210/en.137.9.4058 (Pubitemid 26284685)
6. Bar-On L., Jung S., Defining dendritic cells by conditional and constitutive cell ablation. Immunological Reviews 2010 234 1 76 89 2-s2.0-77349093593 10.1111/j.0105-2896.2009.00875.x
7. Coury F., Annels N., Rivollier A., Olsson S., Santoro A., Speziani C., Azocar O., Flacher M., Djebali S., Tebib J., Brytting M., Egeler R. M., Rabourdin-Combe C., Henter J. I., Arico M., Delprat C., Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nature Medicine 2008 14 1 81 87 2-s2.0-38049072274 10.1038/nm1694
8. Korn T., Bettelli E., Oukka M., Kuchroo V. K., IL-17 and Th17 cells. Annual Review of Immunology 2009 27 485 517 2-s2.0-61949463911 10.1146/annurev.immunol.021908.132710
9. Braun T., Zwerina J., Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Research & Therapy 2011 13, article 235
10. da Costa C. E. T., Annels N. E., Faaij C. M. J. M., Forsyth R. G., Hogendoorn P. C. W., Egeler R. M., Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. Journal of Experimental Medicine 2005 201 5 687 693 2-s2.0-15444376282 10.1084/jem.20041785 (Pubitemid 40395114)
11. Murakami I., Morimoto A., Oka T., IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy. Virchows Archiv 2013 462 2 219 228
12. Yamashita J., Datta N. S., Chun Y. H. P., Yang D. Y., Carey A. A., Kreider J. M., Goldstein S. A., McCauley L. K., Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. Journal of Bone and Mineral Research 2008 23 621 632 (Pubitemid 351575016)
13. Olsson Åkefeldt S., Maisse C., Belot A., Chemoresistance of human monocyte-derived dendritic cells is regulated by IL-17A. PLoS One 2013 8 2 e56865 10.1371/journal.pone.0056865
14. Marsden V. S., Strasser A., Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annual Review of Immunology 2003 21 71 105 2-s2.0-0038021272 10.1146/annurev.immunol.21.120601.141029 (Pubitemid 37174527)
15. Willems F., Amraoui Z., Vanderheyde N., Verhasselt V., Aksoy E., Scaffidi C., Peter M. E., Krammer P. H., Goldman M., Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood 2000 95 11 3478 3482 2-s2.0-0034210209 (Pubitemid 30428480)
16. Nicolò C., Tomassini B., Rippo M. R., Testi R., UVB-induced apoptosis of human dendritic cells: contribution by caspase-dependent and caspase-independent pathways. Blood 2001 97 6 1803 1808 2-s2.0-0035869626 10.1182/blood.V97.6.1803 (Pubitemid 32217249)
17. Youle R. J., Strasser A., The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008 9 1 47 59 2-s2.0-37549048249 10.1038/nrm2308
18. Adams J. M., Cory S., The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007 26 9 1324 1337 2-s2.0-33847328289 10.1038/sj.onc.1210220 (Pubitemid 46328466)
19. Marsden V. S., O'Connor L., O'Reilly L. A., Silke J., Metcalf D., Ekert P. G., Huang D. C. S., Cecconi F., Kuida K., Tomaselli K. J., Roy S., Nicholson D. W., Vaux D. L., Bouillet P., Adams J. M., Strasser A., Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002 419 6907 634 637 2-s2.0-0037057629 10.1038/nature01101
20. Letai A. G., Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Reviews Cancer 2008 8 2 121 132 2-s2.0-38549145044 10.1038/nrc2297 (Pubitemid 351161322)
21. Kelly G. L., Strasser A., The essential role of evasion from cell death in cancer. Advances in Cancer Research 2011 111 39 96 2-s2.0-79959519163 10.1016/B978-0-12-385524-4.00002-7
22. Craig R. W., MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002 16 4 444 454 2-s2.0-0036234124 10.1038/sj/leu/2402416 (Pubitemid 34449724)
23. Hampson P., Hazeldine J., Lord J. M., Neutrophil apoptosis and its induction as a potential treatment for chronic inflammatory disease. Current Opinion in Hematology 2013 20 10 15
24. Chang W. L. W., Baumgarth N., Eberhardt M. K., Lee C. Y. D., Baron C. A., Gregg J. P., Barry P. A., Exposure of myeloid dendritic cells to exogenous or endogenous IL-10 during maturation determines their longevity. Journal of Immunology 2007 178 12 7794 7804 2-s2.0-34250175407 (Pubitemid 46898051)
25. la Sala A., Corinti S., Federici M., Saragovi H. U., Girolomoni G., Ligand activation of nerve growth factor receptor TrKA protects monocytes from apoptosis. Journal of Leukocyte Biology 2000 68 1 104 110 2-s2.0-0033847113
26. Ottina E., Tischner D., Herold M. J., Villunger A., A1/Bfl-1 in leukocyte development and cell death. Experimental Cell Research 2012 318 1291 1303
27. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
28. Miossec P., Kolls J. K., Targeting IL-17 and TH17 cells in chronic inflammation. Nature Reviews Drug Discovery 2012 11 763 776
29. Sieghart W., Losert D., Strommer S., Cejka D., Schmid K., Rasoul-Rockenschaub S., Bodingbauer M., Crevenna R., Monia B. P., Peck-Radosavljevic M., Wacheck V., Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. Journal of Hepatology 2006 44 1 151 157 2-s2.0-28844437366 10.1016/j.jhep.2005.09.010 (Pubitemid 41772529)
30. Thomas S., Quinn B. A., Das S. K., Targeting the Bcl-2 family for cancer therapy. Expert Opinion on Therapeutic Targets 2013 17 61 75
31. van Delft M. F., Wei A. H., Mason K. D., Vandenberg C. J., Chen L., Czabotar P. E., Willis S. N., Scott C. L., Day C. L., Cory S., Adams J. M., Roberts A. W., Huang D. C. S., The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006 10 5 389 399 2-s2.0-33750834023 10.1016/j.ccr.2006.08.027 (Pubitemid 44711953)
32. Vogler M., Butterworth M., Majid A., Walewska R. J., Sun X. M., Dyer M. J. S., Cohen G. M., Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009 113 18 4403 4413 2-s2.0-66149147044 10.1182/blood-2008-08-173310
33. Yecies D., Carlson N. E., Deng J., Letai A., Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010 115 16 3304 3313 2-s2.0-77951442337 10.1182/blood-2009-07-233304
34. Kaufmann S. H., Karp J. E., Svingen P. A., Krajewski S., Burke P. J., Gore S. D., Reed J. C., Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998 91 3 991 1000 2-s2.0-0032006805 (Pubitemid 28078303)
35. Morales A. A., Olsson A., Celsing F., Österborg A., Jondal M., Osorio L. M., High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. International Journal of Cancer 2005 113 5 730 737 2-s2.0-11944251279 10.1002/ijc.20614 (Pubitemid 40101253)
36. Nguyen M., Marcellus R. C., Roulston A., Watson M., Serfass L., Murthy Madiraju S. R., Goulet D., Viallet J., Bélec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R. W., Beauparlant P., Shore G. C., Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2007 104 49 19512 19517 2-s2.0-37649023004 10.1073/pnas.0709443104
37. Wei J., Kitada S., Rega M. F., Emdadi A., Yuan H., Cellitti J., Stebbins J. L., Zhai D., Sun J., Yang L., Dahl R., Zhang Z., Wu B., Wang S., Reed T. A., Lawrence N., Sebti S., Reed J. C., Pellecchia M., Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Molecular Cancer Therapeutics 2009 8 4 904 913 2-s2.0-66449119642 10.1158/1535-7163.MCT-08-1050
38. Rahmani M., Davis E. M., Crabtree T. R., Habibi J. R., Nguyen T. K., Dent P., Grant S., The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Molecular and Cellular Biology 2007 27 15 5499 5513 2-s2.0-34547197343 10.1128/MCB.01080-06 (Pubitemid 47124402)
39. Kitada S., Zapata J. M., Andreeff M., Reed J. C., Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down- regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000 96 2 393 397 2-s2.0-0034661538 (Pubitemid 30463354)
40. Schnaiter A., Stilgenbauer S., Refractory chronic lymphocytic leukemia-new therapeutic strategies. Oncotarget 2010 1 7 472 482 2-s2.0-79957984650
41. Jackson J. R., Patrick D. R., Dar M. M., Huang P. S., Targeted anti-mitotic therapies: can we improve on tubulin agents? Nature Reviews Cancer 2007 7 2 107 117 2-s2.0-33846523617 10.1038/nrc2049 (Pubitemid 46160987)
42. Wertz I. E., Kusam S., Lam C., Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011 471 110 114
43. Genovese M. C., Van den Bosch F., Roberson S. A., Bojin S., Biagini I. M., Ryan P., Sloan-Lancaster J., LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis and Rheumatism 2010 62 4 929 939 2-s2.0-77950535421 10.1002/art.27334
44. Pettit A. R., MacDonald K. P., O'Sullivan B., Thomas R., Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis and Rheumatism 2000 43 791 800
45. Thomas R., MacDonald K. P. A., Pettit A. R., Cavanagh L. L., Padmanabha J., Zehntner S., Dendritic cells and the pathogenesis of rheumatoid arthritis. Journal of Leukocyte Biology 1999 66 2 286 292 2-s2.0-0032776916 (Pubitemid 29379170)
46. Wenink M. H., Han W., Toes R. E., Radstake T. R., Dendritic cells and their potential implication in pathology and treatment of rheumatoid arthritis. Handbook of Experimental Pharmacology 2009 188 81 98 2-s2.0-60549095495 10.1007/978-3-540-71029-5-4
47. Jongbloed S. L., Lebre M. C., Fraser A. R., Gracie J. A., Sturrock R. D., Tak P. P., McInnes I. B., Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Research and Therapy 2006 8 1, article R15 2-s2.0-70350513152 10.1186/ar1864
48. Zvaifler N. J., Steinman R. M., Kaplan G., Lau L. L., Rivelis M., Identification of immunostimulatory dendritic cells in the synovial effusions of patients with rheumatoid arthritis. The Journal of Clinical Investigation 1985 76 2 789 800 2-s2.0-0021869327 (Pubitemid 15023137)
49. Leung B. P., Conacher M., Hunter D., McInnes I. B., Liew F. Y., Brewer J. M., A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. Journal of Immunology 2002 169 12 7071 7077 2-s2.0-0037114178 (Pubitemid 36899295)
50. Esensten J. H., Wofsy D., Bluestone J. A., Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nature Reviews Rheumatology 2009 5 10 560 565 2-s2.0-70349969840 10.1038/nrrheum.2009.183
51. Khan S., Greenberg J. D., Bhardwaj N., Dendritic cells as targets for therapy in rheumatoid arthritis. Nature Reviews Rheumatology 2009 5 10 566 571 2-s2.0-70349961777 10.1038/nrrheum.2009.185
52. Liu H., Eksarko P., Temkin V., Haines G. K., Perlman H., Koch A. E., Thimmapaya B., Pope R. M., Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. Journal of Immunology 2005 175 12 8337 8345 2-s2.0-29144526644 (Pubitemid 41798400)
53. Scatizzi J. C., Hutcheson J., Pope R. M., Firestein G. S., Koch A. E., Mavers M., Smason A., Agrawal H., Haines G. K., Chandel N. S., Hotchkiss R. S., Perlman H., Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis and Rheumatism 2010 62 2 441 451 2-s2.0-75749091858 10.1002/art.27198
54. Oliveira R. D., Fontana V., Junta C. M., Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy. The Journal of Rheumatology 2012 39 1524 1532
55. Segura E., Touzot M., Bohineust A., Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013 38 2 336 348
56. Stoop J. N., Robinson J. H., Hilkens C. M. U., Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Annals of the Rheumatic Diseases 2011 70 9 1526 1533 2-s2.0-79961235625 10.1136/ard.2011.151654
57. Badalian-Very G., Vergilio J. A., Fleming M., Rollins B. J., Pathogenesis of langerhans cell histiocytosis. Annual Review of Pathology 2013 8 1 20
58. Maarten Egeler R., van Halteren A. G. S., Hogendoorn P. C. W., Laman J. D., Leenen P. J. M., Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunological Reviews 2010 234 1 213 232 2-s2.0-77349107124 10.1111/j.0105-2896.2009.00883.x
59. Allen C. E., Li L., Peters T. L., Leung H. C. E., Yu A., Man T. K., Gurusiddappa S., Phillips M. T., Hicks M. J., Gaikwad A., Merad M., McClain K. L., Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. Journal of Immunology 2010 184 8 4557 4567 2-s2.0-77952765452 10.4049/jimmunol.0902336
60. Hutter C., Kauer M., Simonitsch-Klupp I., Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells. Blood 2012 120 5199 5208
61. Senechal B., Elain G., Jeziorski E., Grondin V., De Serre N. P. M., Jaubert F., Beldjord K., Lellouch A., Glorion C., Zerah M., Mary P., Barkaoui M., Emile J. F., Boccon-Gibod L., Josset P., Debré M., Fischer A., Donadieu J., Geissmann F., Expansion of regulatory T cells in patients with langerhans cell histiocytosis. PLoS Medicine 2007 4 8, article e253 2-s2.0-34548396433 10.1371/journal.pmed.0040253 (Pubitemid 47358173)
62. Aricò M., Nichols K., Whitlock J. A., Arceci R., Haupt R., Mittler U., Kühne T., Lombardi A., Ishii E., Egeler R. M., Danesino C., Familial clustering of Langerhans cell histiocytosis. British Journal of Haematology 1999 107 4 883 888 2-s2.0-0033401827 (Pubitemid 30020164)
63. Badalian-Very G., Vergilio J. A., Degar B. A., Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010 116 1919 1923
64. Sahm F., Capper D., Preusser M., BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012 120 28 34
65. Satoh T., Smith A., Sarde A., B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One 2012 7 e33891
66. Nichols K. E., Arceci R. J., BRAF, a piece of the LCH puzzle. Blood 2010 116 11 1825 1827 2-s2.0-77956929928 10.1182/blood-2010-06-289934
67. Bank M. I., Gudbrand C., Rengtved P., Carstensen H., Fadeel B., Henter J. I., Petersen B. L., Immunohistochemical detection of the apoptosis-related proteins FADD, FLICE, and FLIP in Langerhans cell histiocytosis. Journal of Pediatric Hematology/Oncology 2005 27 6 301 306 2-s2.0-21244490862 10.1097/01.mph.0000168725.57143.52 (Pubitemid 40885158)
68. Savell V. H. Jr., Sherman T., Scheuermann R. H., Siddiqui A. M., Margraf L. R., Bcl-2 expression in Langerhans' cell histiocytosis. Pediatric and Developmental Pathology 1998 1 3 210 215 2-s2.0-0032057050 (Pubitemid 128542129)
69. Schouten B., Egeler R. M., Leenen P. J. M., Taminiau A. H. M., van den Broek L. J. C. M., Hogendoorn P. C. W., Expression of cell cycle-related gene products in Langerhans cell histiocytosis. Journal of Pediatric Hematology/Oncology 2002 24 9 727 732 2-s2.0-0036901064 10.1097/00043426- 200212000-00009 (Pubitemid 35448737)
70. Marchal J., Kambouchner M., Tazi A., Valeyre D., Soler P., Expression of apoptosis-regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis. Histopathology 2004 45 1 20 28 2-s2.0-3242767545 10.1111/j.1365-2559.2004.01875.x (Pubitemid 38969558)
71. Michaloglou C., Vredeveld L. C. W., Mooi W. J., Peeper D. S., BRAFE600 in benign and malignant human tumours. Oncogene 2008 27 7 877 895 2-s2.0-38949131824 10.1038/sj.onc.1210704 (Pubitemid 351225383)
72. de Graaf J. H., Tamminga R. Y., Dam-Meiring A., Kamps W. A., Timens W., The presence of cytokines in Langerhans' cell histiocytosis. The Journal of Pathology 1996 180 400 406 (Pubitemid 27014078)
73. Egeler R. M., Favara B. E., van Meurs M., Laman J. D., Claassen E., Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 1999 94 12 4195 4201 2-s2.0-0032778769
74. Comabella M., Montalban X., Münz C., Lünemann J. D., Targeting dendritic cells to treat multiple sclerosis. Nature Reviews Neurology 2010 6 9 499 507 2-s2.0-77956341214 10.1038/nrneurol.2010.112
75. Palucka K., Banchereau J., Mellman I., Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010 33 4 464 478 2-s2.0-77958454596 10.1016/j.immuni.2010.10.007
76. Caminschi I., Maraskovsky E., Heath W. R., Targeting dendritic cells in vivo for cancer therapy. Frontiers in Immunology 2012 3, article 13